Non-Executive Director Appointment
30 Septiembre 2021 - 1:02AM
Non-Executive Director Appointment
Synairgen
plc(‘Synairgen’ or the ‘Company’)
Non-Executive Director
Appointment
Southampton, UK –
30 September
2021: Synairgen plc (LSE: SNG), the drug
discovery, development and commercialisation company, is pleased to
announce the appointment of Theodora Harold as an independent
Non-Executive Director of the Company and Chair of the Audit
Committee with immediate effect.
Theodora has over 20 years’ experience in the
biotech sector and is currently CEO of Crescendo Biologics Ltd. She
was previously part of the founding management teams of both
PsiOxus Therapeutics Ltd and Mission Therapeutics Ltd. Theodora has
previous non-executive director experience at Chronos Therapeutics
Ltd.
Theodora is also a Chartered Accountant having
qualified at PricewaterhouseCoopers.
Simon Shaw, Chair of
Synairgen, commented: "I am delighted to have
Theodora joining the Board at this pivotal transition point for
Synairgen. Her breadth and depth of experience brings a welcome new
perspective to the Board and her expertise in the life sciences and
biotech industries will be of great value to Synairgen particularly
as we move into a new phase of rapid change with our Phase III
trial for SNG001 (inhaled interferon beta) nearing completion.”
Theodora Harold, newly
appointed Non-Executive Director and Chair of the
Audit Committee added: “Building on the ground-breaking
work of Professor Sir Stephen Holgate and his team at University of
Southampton, Synairgen is at an important stage in its growth as it
looks to expand access of this innovative inhaled interferon beta
treatment to patients, particularly those severely ill with
COVID-19. This is an exciting time to join the Synairgen team, and
I look forward to working with Simon and the Board in pursuing a
successful future for the Company.”
As required under Schedule Two, paragraph (g) of
the AIM Rules for Companies, further disclosures on Ms Harold are
as follows:
Ms Theodora Caroline Harold, aged 47, has held
the following directorships and/or partnerships in the past five
years:
Current directorships and/or
partnerships:
- Crescendo Biologics Limited
Past directorships and/or
partnerships:
- Chronos Therapeutics Ltd
- Dreadnought Ltd
- Cambridge Consultancy Services
Ltd
- Orlixus Ltd
Ms Harold holds no ordinary shares in the
Company.
There is no further information on Ms Harold
required to be disclosed under Schedule Two, paragraph (g) of the
AIM Rules for Companies.
For further enquiries, please contact:
Synairgen plcRichard Marsden, Chief Executive
OfficerJohn Ward, Chief Financial OfficerBrooke Clarke, Head of
CommunicationsTel: + 44 (0) 23 8051 2800
finnCap (NOMAD and Joint
Broker)Geoff Nash, Kate Bannatyne, Charlie Beeson
(Corporate Finance)Alice Lane, Sunil de Silva (ECM)Tel: + 44 (0) 20
7220 0500
Numis Securities Limited (Joint Broker)James
Black, Freddie Barnfield, Duncan MonteithTel: + 44 (0) 20 7260
1000
Consilium Strategic Communications
(UK Financial Media and Investor
Relations)Mary-Jane Elliott, Jessica Hodgson, Carina Jurs
synairgen@consilium-comms.comTel: +44 (0) 20 3709 5700
MKC Strategies, LLC (US Media
Relations)Mary ConwayMConway@MKCStrategies.com Tel: +1 516
606 6545
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company
focused on drug discovery, development and commercialisation. The
Company’s primary focus is developing SNG001 (inhaled interferon
beta) for the treatment of COVID-19 as potentially the first
host-targeted broad-spectrum antiviral treatment delivered directly
into the lungs. Granted Fast Track status from the US Food and Drug
Administration (FDA) and deemed an Urgent Public Health study by
the UK's National Institute for Health Research (NIHR), Synairgen’s
Phase III clinical programme is currently evaluating nebulised
SNG001 in patients across 17 countries. In a Phase II trial in
hospitalised COVID-19 patients, SNG001 demonstrated a greater than
twofold chance of recovery to ‘no limitation of activities’ versus
placebo.
Founded by University of Southampton Professors
Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003,
Synairgen is quoted on AIM (LSE: SNG). For more information about
Synairgen, please see www.synairgen.com.
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024